Granted Patent
B2
US 12,551,540 · App. 17/709,166 · Granted Feb 17, 2026
Dosing and administration of recombinant L-asparaginase
Assignee:
Jazz Pharmaceuticals Ireland Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides compositions and methods for treating a disease treatable by asparagine depletion in a human subject comprising dosing a human subject with L-asparaginase.
Claims (30)
1 . A method of treating cancer in a human subject in need thereof, said method comprising administering to the human subject L-asparaginase, other than an Escherichia coli derived asparaginase, as a set of time-ordered doses;
wherein the set of time-ordered doses comprises two series of three doses, wherein a first dose and a second dose are each 25 mg/m 2 and a third dose is 50 mg/m 2 ,
wherein the first, the second and the third dose are administered on a Monday, Wednesday and Friday, respectively, and wherein the L-asparaginase is a tetramer wherein each monomer of the tetramer comprises SEO ID NO:1,
wherein the doses at 25 mg/m 2 are administered intravascularly and the doses at 50 mg/m 2 are administered intramuscularly, and
wherein the cancer is a blood cell cancer treatable by asparagine depletion, thereby treating cancer in the subject.
2 . The method of claim 1 , wherein the human subject exhibited hypersensitivity to the Escherichia coli derived asparaginase.
3 . The method of claim 1 , wherein the human subject is an adult.
4 . The method of claim 1 , wherein the human subject is pediatric.
5 . The method of claim 1 , wherein the L-asparaginase demonstrates less than 6% aggregation.
6 . The method according to claim 1 , wherein the L-asparaginase is co-administered with one or more other chemotherapeutic agents as part of a multi-agent chemotherapeutic regimen.
7 . A method of substituting a treatment of a human subject for cancer, wherein the human subject is in need thereof, said method comprising administering to the human subject, as a substitute for an Escherichia coli derived asparaginase, a series of six doses of an L-asparaginase,
wherein a first dose and a second dose are each 25 mg/m 2 and a third dose is 50 mg/m 2 ,
wherein the first, the second and the third dose are administered on a Monday, Wednesday and Friday, respectively, and
wherein the L-asparaginase is a tetramer wherein each monomer of the tetramer comprises SEO ID NO: 1
wherein the doses at 25 mg/m 2 are administered intravascularly and the doses at 50 mg/m 2 are administered intramuscularly,
wherein the L-asparaginase is not an Escherichia coli derived asparaginase, and
wherein the cancer is a blood cell cancer treatable by asparagine depletion, thereby substituting a treatment of the human subject for cancer.
8 . The method of claim 7 , wherein each respective dose of the Escherichia coli derived asparaginase in a plurality of doses of the Escherichia coli derived asparaginase is separately substituted with an instance of the series of six doses of the L-asparaginase.
9 . The method of claim 7 , wherein the human subject exhibited hypersensitivity to the Escherichia coli derived asparaginase.
10 . The method of claim 7 , wherein the human subject is an adult.
11 . The method of claim 7 , wherein the human subject is pediatric.
12 . The method of claim 7 , wherein the L-asparaginase demonstrates less than 6% aggregation.
13 . The method according to claim 7 , wherein the L-asparaginase is co-administered with one or more other chemotherapeutic agents as part of a multi-agent chemotherapeutic regimen.
14 . The method according to claim 1 , wherein the cancer is acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL).
15 . The method according to claim 1 , wherein the cancer is acute myeloid leukemia (AML).
16 . The method according to claim 1 , wherein the cancer is diffuse large B-cell lymphoma (DLBCL).
17 . The method according to claim 7 , wherein the cancer is acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL).
18 . The method according to claim 7 , wherein the cancer is acute myeloid leukemia (AML).
19 . The method according to claim 7 , wherein the cancer is diffuse large B-cell lymphoma (DLBCL).
20 . The method of claim 1 , wherein the first dose is administered on a Monday, the second dose is administered on a Wednesday, and the third dose is administered on a Friday.
Assignments (2)
SECURITY AGREEMENT
Recorded Apr 21, 2026
From: CAVION, INC.; JAZZ PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED; JAZZ PHARMACEUTICALS RESEARCH UK LIMITED; JAZZ PHARMACEUTICALS THERAPEUTICS, INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 075442/0203 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 8, 2022
From: CHOI, MI RIM; LIN, TONG; SILVERMAN, JEFFREY
To: JAZZ PHARMACEUTICALS IRELAND LTD.
Reel/Frame 061026/0435 →
Continuity (2)
Provisional Application
63168224
· Mar 30, 2021
References Cited (163)
US 9322008B2
· Kundu et al.
· 2016
[cited by applicant]
US 20180371446A1
· Friedrich
· 2018
[cited by examiner]
US 20200277379A1
· Bostwick et al.
· 2020
[cited by applicant]
US 20220313798A1
· Choi
· 2022
[cited by examiner]
CN 102657852A
· 2012
[cited by applicant]
EP 3418383A1
· 2018
[cited by applicant]
WO WO2011003633A1
· 2011
[cited by applicant]
WO WO2019109018A1
· 2019
[cited by examiner]
WO WO2020014581A1
· 2020
[cited by applicant]
WO WO2020089743A1
· 2020
[cited by applicant]
WO WO2020102427A1
· 2020
[cited by applicant]
WO WO2020136666A1
· 2020
[cited by applicant]
WO WO2021032997A1
· 2021
[cited by applicant]
WO WO2021078988A1
· 2021
[cited by applicant]
WO WO2022087589A1
· 2022
[cited by applicant]
WO 2022217231A1
· 2022
[cited by applicant]
Lin et. al. (Population pharmacokinetic (PK) model development and simulation for recombinant crisantaspase produced in pseudomonas fluorescence (RC-P), 2020 (Abstract/Poster presented Mar. 18-21, 2020—Clinical Pharmaco…
[cited by examiner]
Vrooman et. al. (Activity and Toxicity of IV Erwinia Asparaginase Following Allergy to
[cited by examiner]
Covini et al., “Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase”, Recent Patents on Anti-Cancer Drug Discovery 7: 4-13 (Year: 2012).
[cited by examiner]
Balcao and Vila, “Structural and functional stabilization of protein entities: state of the art”, Advanced Drug Delivery Reviews 93: 25-41 (Year: 2015).
[cited by examiner]
Lomelino et al.,“Asparagine synthetase: Function, structure, and role in disease”, Journal of Biological Chemistry 292(49): 19952-19958 (Year: 2017).
[cited by examiner]
Sun et al.,“SLC1A3 contributes to L-asparaginase resistance in solid tumors”, The EMBO Journal 38: e102147 (Year: 2019).
[cited by examiner]
Salzer et al.,“Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group”, Blood 122(4): 507-514 (Year: 2013).
[cited by examiner]
Panetta et al., “Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase”, Pediatr Blood Cancer 67: e28244 pp. 1-4 (Year: 2020).
[cited by examiner]
Van der Sluis et al., “Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation”, Haematologica 100(3): 279-285 (Year: 2016).
[cited by examiner]
WO, International Search Report and Written Opinion for International Patent Application No. PCT/US2021/032627, 20 pages, Apr. 5, 2022.
[cited by applicant]
Adamson, RH et al. Evaluation of the embryotoxic activity of L asparaginase. Arch Int Pharmacodyn 1970;186(2):310-20.
[cited by applicant]
American Cancer Society. Types of Non-Hodgkin Lymphoma in Children; dated Jan. 27, 2016. Available at: https://www.cancer.org/cancer/childhood-non-hodgkin-lymphoma/treating/by-stage.html. Accessed Mar. 20, 2020.
[cited by applicant]
American Cancer Society: Acute Lymphocytic Leukemia (ALL). Atlanta: American Cancer Society; 2021. Available at: https://www.cancer.org/cancer/childhood-non-hodgkin-lymphoma/about/types-non-hodgkin-children.html. Access…
[cited by applicant]
Ashworth, Lae et al., Comparison of the L-Asparaginases from
[cited by applicant]
Asparlas, Summary Basis of Approval. Application #761102, Approval Date: Dec. 20, 2018 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761102Orig1s000TOC.cfm.
[cited by applicant]
Asselin, B et al., Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leukemia & lymphoma. Aug. 3, 2015; 56(8):2273-80.
[cited by applicant]
Avramis, VI et al., A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukem…
[cited by applicant]
Ballerini, A et al. Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations. Cancer Chemother Pharmacol Jun. 2017;79(6):1267-1271. doi: 10.1007/…
[cited by applicant]
Barry, E et al., Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium protocols. Journal of clinical oncology. Mar. 1, 2007;…
[cited by applicant]
Bassan, R et al., Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. European journal of Haematology. May 2016; 96(5):447-60.
[cited by applicant]
Benbough, JE et al. The effect of chemical modification of L asparaginase on its persistence in circulating blood of animals. Biochem Pharmacol 1979;28:833.
[cited by applicant]
Berenbaum, MC. Immunosuppression by L-asparaginase. Nature Feb. 7, 1970;225(5232):550-2. doi: 10.1038/225550a0.
[cited by applicant]
Blazek, R et al., Improvement in the persistence of microbial asparaginase and glutaminase in the circulation of the rat by chemical modifications. Biochim Biophys Acta 1981;677:220-4.
[cited by applicant]
Borek, D et al., Sequence analysis of enzymes with asparaginase activity. Acta Biochim Pol 2001;48(4):893-902.
[cited by applicant]
Caruso, V et al., Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. Oct. 1, 2006; 108(7):2216-22.
[cited by applicant]
Celle, G et al. Toxic and immunodepressive effects of L-asparaginase from
[cited by applicant]
Chen, Q. et al. Autophagy suppression potentiates the anti-glioblastoma effect of asparaginase in vitro and in vivo. Oncotarget 2017;8(53):91052-66.
[cited by applicant]
Chien, WW et al., Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant
[cited by applicant]
Chiu, M et al., Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts. Br J Cancer 2014;111:1159-67.
[cited by applicant]
Covini, D. et al. Expanding targets for a metabolic therapy of cancer: L asparaginase. Recent Pat Anticancer Drug Discov 2012;7:4-13.
[cited by applicant]
Dana-Farber Cancer Institute: Childhood Lymphoblastic Lymphoma. Available at: https://www.dana-farber.org/childhood-lymphoblastic-lymphoma/. Accessed Feb. 8, 2021.
[cited by applicant]
Davies, B et al., Physiological parameters in laboratory animals and humans. Pharm Res 1993;10(7):1093-95.
[cited by applicant]
DeAngelo, DJ et al., Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. Mar. 2015; 29(3):526-34.
[cited by applicant]
Durden, DL et al., Kinetic analysis of hepatotoxicity associated with antineoplastic asparaginases. Cancer Res 1983;43(4):1602-5.
[cited by applicant]
Duval, M et al., Comparison of
[cited by applicant]
Emadi, A et al., Asparaginase in the treatment of non-ALL hematologic malignancies Cancer Chemother Pharmacol 2014;73:875-83.
[cited by applicant]
Erwinaze® (asparaginase Erwinia chrysanthemi) Prescribing Information (withdrawn 2021). Jazz Pharmaceuticals, Inc.; Palo Alto, CA.
[cited by applicant]
Erwinase (L-asparaginase from Erwinia chrysanthemi) for injection, intramuscular or intravenous use. SmPC. Porton Biopharma Ltd. Ireland. Mar. 2021. Available from: https://mri.cts-mrp.eu/Human/Downloads/NL_H_5322_001_F…
[cited by applicant]
European Medicines Agency (EMA). Guideline on bioanalytical method validation. Jul. 21, 2011 (Effective: Feb. 1, 2012) Available at: https://www.ema.europa.eu/en/bioanalytical-method-validation.
[cited by applicant]
European Medicines Agency (EMA). Guideline on immunogenicity assessment of therapeutic proteins. May 18, 2017 (Effective: Dec. 1, 2017). Available at: https://www.ema.europa.eu/en/immunogenicity-assessment-biotechnology…
[cited by applicant]
Figueiredo, L et al., Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to
[cited by applicant]
Food and Drug Administration (FDA.) Guidance for Industry: Bioanalytical method validation. May 2018.
[cited by applicant]
[cited by applicant]
Gervais, D. Acidic isoforms of Erwinase form part of the product: Correlation with clinical experience. Biologicals Mar. 2020;64:28-33. doi: 10.1016/j.biologicals.2020.01.005.
[cited by applicant]
Gupta, S et al., Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology. Jun. 10, 2020; 38(17):1897-905.
[cited by applicant]
Hall, JG. The partitioning of L-asparaginase between blood and lymph. In: E Grundmann and Oeltgen HF. Recent Results in Cancer Research, vol. 33. Berlin, East Germany; Springer-Verlag. 1970.
[cited by applicant]
Han, T et al., In vitro blastogenesis inhibited by Erwinia carotovora L-asparaginase. Nat New Biol Sep. 13, 19723;239(89):50-1. doi: 10.1038/newbio239050a0.
[cited by applicant]
Hernandez-Ilias et al., “A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-PO in Healthy Adults”, Blood,, American Society of Hematolo…
[cited by applicant]
Hijiya, N et al., Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leukemia & lymphoma. Apr. 2, 2016; 57(4):748-57.
[cited by applicant]
Horowitz et al., Asparagine synthetase activity of mouse leukemias. Science May 3, 1968;160(3827):533-5. doi: 10.1126/science.160.3827.533.
[cited by applicant]
Howard, SC et al., Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood reviews. Dec. 1, 2002; 16(4):225-43.
[cited by applicant]
Kanda, P. et al., Determination of glycation levels in Erwinia chrysanthemi asparaginase drug product by liquid chromatography-mass spectrometry. Eur J Pharm Sci Mar. 30, 2020;145:105253. doi: 10.1016/j.ejps.2020.105253.
[cited by applicant]
Karamitros, CS et al., Human 60-kDa lysophospholipase contains an N-terminal L-asparaginase domain which is allosterically regulated by L-asparagine. J Biol Chem 2014;289(19):12962-75.
[cited by applicant]
Kearney, SL et al., Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatric Blood & Cancer. Aug. 2009; 53(2):162-7.
[cited by applicant]
Kidd J(a). Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit ser…
[cited by applicant]
Kidd J(b). Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. II. Studies on the nature of the active serum constituent: Histological mechanism of the regression: Tests for effects…
[cited by applicant]
Kloos, RQ et al., Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. Mar. 1, 2020; 38(7):715-24.
[cited by applicant]
Knoderer, HM et al., Predicting asparaginase-associated pancreatitis. Pediatric blood & cancer. Oct. 15, 2007; 49(5):634-9.
[cited by applicant]
Kotzia, GA et al., I-Asparaginase from
[cited by applicant]
Leukemia Foundation. Lymphoblastic Lymphoma, dated Jun. 18, 2019. Available at: https://www.leukaemia.org.au/disease-information/lymphomas/non-hodgkin-lymphoma/other-non-hodgkin-lymphomas/lymphoblastic-lymphoma/. Access…
[cited by applicant]
Lin, T. et al., “Population pharmacokinetic (PK) model development and simulation for recombinant crisantaspase produced in pseudomonas fluorescens (RC-P)”, Clinical Pharmacology and Therapeutics, vol. 107, No. S1, Jan.…
[cited by applicant]
Lin, T. et al., “A Randomized Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult Volunteers”, Clin Transl Sci. May 2021;14(3):870-879.
[cited by applicant]
Lin, T. et al., “Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP-458)”, Clin Pharmacol Drug Dev. Dec. 2021;10(12):1503-1513.
[cited by applicant]
Liu, C et al., Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia. Journal of Clinical Oncology. Jun. 20, 2016; 34(18):2133-2140.
[cited by applicant]
Maese, L et al., “Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?” 2021, Submitted to Pediatric Blood & Cancer.
[cited by applicant]
Maese L et al., “Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas fluorescens (RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymophoma (LBL) Foll…
[cited by applicant]
Maese L et al., A Phase 2/3 study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to
[cited by applicant]
Mayo Clinic. Acute Lymphocytic Leukemia. Available at: https://www.mayoclinic.org/diseases-conditions/acute-lymphocytic-leukemia/symptoms-causes/syc-20369077. Accessed Feb. 8, 2021.
[cited by applicant]
Minetto, P et al., Glutamine-dependence targeting by asparaginase significantly increases anti-myeloma activity of proteasome inhibitors. [Abstract 1796] Blood 2017;130 (Suppl 1).
[cited by applicant]
Minton, NP et al., Nucleotide sequence of the
[cited by applicant]
Moghrabi, A et al., Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. Feb. 1, 2007;109(3):896-904.
[cited by applicant]
Nachman, JB et al., Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. New England Journal of Medicine. Jun. 4, 1998;338(23):1663-71.
[cited by applicant]
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 1.2020, dated Jan. 15, 2020.
[cited by applicant]
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pediatric Acute Lymphoblastic Leukemia. Version 2.2020, dated Nov. 25, 2019.
[cited by applicant]
Neish et al., Inhibition of Rd/3 rat sarcoma by L-asparaginase alone and in combination with sodium para-amino-salicylate. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1973;79(2):78-84. doi: 10.1007/BF00284381.
[cited by applicant]
Nguyen, HA et al., A novel L-asparaginase with low L-glutaminase coactivity is highly efficacious against both T and B cell acute lymphoblastic leukemias in vivo. Cancer Res 2018;78(6):1549-60.
[cited by applicant]
Nomme, J et al., Elucidation of the specific function of the conserved threonine triad responsible for human L-asparaginase autocleavage and substrate hydrolysis. J Mol Biol 2014;426:2471-85.
[cited by applicant]
Ogawa, C. et al., Treatment Outcome of Discontinued L-Asparaginase in Children with Standard-Risk Acute Lymphoblastic Leukemia: Tokyo Children's Cancer Study Group (TCCSG) Study L99-15. Blood 2005; 106 (11): 878.
[cited by applicant]
Okusanya, O et al., Intramuscular (IM) or intravenous (IV): Impact of Erwinia asparaginase route of administration on asparaginase activity. Journal of Clinical Oncology 2015; 33:15_suppl, 10031.
[cited by applicant]
Panetta et al., “Higher plasma asparaginase activity after intramuscular than intravenous Erwina asparaginase”, Pediatric Blood Cancer 2020:e28244.
[cited by applicant]
Panosyan, EH et al., Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. Journal of Pediatric Hematology/Oncology. Apr. 1, 2…
[cited by applicant]
Panosyan, EH et al., Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res Mar.-Apr. 2004;24(2C):1121-5.
[cited by applicant]
Parmentier, JH et al., Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines. Leuk Res 2015;39:757-62.
[cited by applicant]
Parsons, SK et al., . Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood, The Journal of the American Society of Hematology. Mar. 15, 1997; 89(6):1886-95.
[cited by applicant]
Patel, N et al., A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. J Clin Invest Jul. 2009;119(7):1964-73. doi: 10.1172/JCI37977.
[cited by applicant]
Payne, JH et al., Thrombosis and acute lymphoblastic leukaemia. British journal of haematology. Aug. 2007; 138(4):430-45.
[cited by applicant]
Peng, H. et al., Hypermethylation of CpG islands in the mouse asparagine synthetase gene: relationship to asparaginase sensitivity in lymphoma cells. Partial methylation in normal cells. Br J Cancer 2001;85(6):930-5. do…
[cited by applicant]
Pieters, R et al., L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. Jan. 15, 2011; 117(2):238-49.
[cited by applicant]
Place, AE et al., Intravenous pegylated asparaginase versus intramuscular native
[cited by applicant]
Plourde, PV et al., Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatric blood & cancer. Jul. 2014; 61(7):1232-8.
[cited by applicant]
Pui, CH et al., Treatment of acute lymphoblastic leukemia. New England Journal of Medicine. Jan. 12, 2006; 354(2):166-78.
[cited by applicant]
Raetz, EA et al., Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2010 32(7):554-63. doi: 10.1097/MPH.0b013e3181e6f003.
[cited by applicant]
Raja, RA et al., Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL 2008 protocol. British journal of haematology. Apr. 2014;165(1):126-33.
[cited by applicant]
Rank, CU et al., Asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the NOPHO ALL2008 treatment of patients 1-45 years of age. Journal of clinical oncology. Jan. 10, 2020;38(2):145.
[cited by applicant]
Riccardi, R et al., L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981;41(11 Pt 1):4554-8.
[cited by applicant]
Roberts, J. et al., A comparative study of the antitumor effectiveness of
[cited by applicant]
Runzi, M et al., Drug-associated pancreatitis: facts and fiction. Pancreas. Jul. 1, 1996; 13(1):100-9.
[cited by applicant]
Rutter, DA et al., The influence of the iso-electric point of L-asparaginase upon its persistence in the blood. Br J Exp Pathol 1971;52:610.
[cited by applicant]
Ryu IH, Long-Term Survival after T-cell Lymphoblastic Lymphoma Treated with One Cycle of Hyper-CVAD Regimen. Cancer Res Treat. 2015; 47(1):115-119.
[cited by applicant]
Sahu, S et al., L-asparaginase (Leunase) induced pancreatitis in childhood acute lymphoblastic leukemia. Pediatric hematology and oncology. Jan. 1, 1998;15(6):533-8.
[cited by applicant]
Sallan, W et al., Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Research. Nov. 1, 1983; 43(11):5601-7.
[cited by applicant]
Salzer, WL et al., Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood. Jul. 25, 2013; 122(4):507-14.
[cited by applicant]
Salzer, WL et al., Development of asparaginase
[cited by applicant]
Salzer, WL et al., Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leukemia & lymphoma. Aug. 3, 2018; 59(8):1797-806.
[cited by applicant]
Samarasinghe, S et al., . Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. British journal of haematology. Sep. 2013;1…
[cited by applicant]
Sanghez, V et al., Efficacy of asparaginase
[cited by applicant]
Serravalle, S et al., Synergistic cytotoxic effect of L-asparaginase combined with decitabine as a demethylating agent in pediatric T-ALL, with specific epigenetic signature. Biomed Res Int 2016; Article ID 1985750, 6 p…
[cited by applicant]
Siemers, RF et al., High-dose cytosine arabinoside-associated pancreatitis. Cancer. Oct. 15, 1985; 56(8):1940-2.
[cited by applicant]
Silverman, LB et al., Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood, The Journal of the American Society of Hematology. Mar. 1, 2001; 97(5):1211…
[cited by applicant]
Sindhu, R. et al., “Expression and characterization of recombinant L-asparginase from
[cited by applicant]
Sobin, LH et al., Alterations in protein and nucleic acid metabolism of lymphoma 6C
[cited by applicant]
Song, P et al., The role of autophagy in asparaginase-induced immune suppression of macrophages Cell Death Dis 2017;8:e2721; doi:10.1038/cddis.2017.144 2017.
[cited by applicant]
Song, P et al., Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells. Oncotarget 2015;6(6):3861-73.
[cited by applicant]
Stock, W et al., What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Gr…
[cited by applicant]
Stock, W et al., Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leukemia & Lymphoma. Dec. 1, 2011; 52(12):2237-53.
[cited by applicant]
Stock, W et al., A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. Apr. 4, 2019; 133(14):1548-59.
[cited by applicant]
Summary of Product Characteristics. Kidrolase. https://pp.jazzpharma.com/pi/kidrolase.ca.PM-en.pdf. Accessed Mar. 5, 2021.
[cited by applicant]
Tong, WH et al., A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia, Blood. Mar. 27, 2014; 123(13): 2026-2033.
[cited by applicant]
Ueno, T. et al., Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase. Leukemia 1997;11:1858-61.
[cited by applicant]
Uren, JR et al., Immunological and pharmacological characterization of poly-DL-alanyl-modified
[cited by applicant]
Uren, JR et al., Improvement in the therapeutic, immunological, and clearance properties of
[cited by applicant]
Van Der Sluis, IM et al., Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica 2016;100(3):279-85.
[cited by applicant]
Vora, A et al., Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UK…
[cited by applicant]
Vrooman, LM et al., Erwinia asparaginase after allergy to
[cited by applicant]
Vrooman, LM et al., Postinduction dexamethasone and individualized dosing of
[cited by applicant]
Vrooman, L. et al., “Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to
[cited by applicant]
Wade, HE et al., A new L-asparaginase with antitumour activity? Lancet 1968;2(7571):776-7. doi: 10.1016/s0140-6736(68)90977-x.
[cited by applicant]
Weaver, G., Steroid-induced pancreatitis. Gastroenterology. Mar. 1, 1982; 82(3):601.
[cited by applicant]
Wolthers, BO et al., Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL 2008 protocol. Leukemia. Feb. 2017a; 31(2):325-32.
[cited by applicant]
Wolthers, BO et al., Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia: an observational Ponte di Legno Toxicity Working Group study. The Lancet Oncology. Sep 1, 2017b; 18(9):1238-48.
[cited by applicant]
Woo, MH et al., Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. Journal of Clinical Oncology. Apr. 7, 2000; 18(7):1525-32.
[cited by applicant]
Young, DM et al., Clinicopathologic and ultrastructural studies of L asparaginase-induced hypocalcemia in rabbits. An experimental animal model of acute hypoparathyroidism. Lab Invest 1973;29(4):374-86.
[cited by applicant]
Zalewska-Szewczyk, B. et al., “The cross-reactivity of anti-asparaginase antibodies against different l-asparginase preparations”, Clinical and Experimental Medicine, Springer-Verlaf, MI, vol. 9, No. 2, Jan. 30, 2009, p…
[cited by applicant]
Study No. SSARL-DPH-72-02; The toxicity of L-asparaginase from Erwinia carotovora (NSC 106977) in rabbits.
[cited by applicant]
Study No. SSARL-DPH-72-05; Effects of
[cited by applicant]
Study No. SSARL-DPH-69-00; Toxicity studies on Erwinia carotovora L-asparaginase Batch Aug. 17, 1969 (NSC 109229) following daily IV administration to rhesus monkeys.
[cited by applicant]
Study No. SSARL-DPH-71-01; Comparative Toxicity of IV Administration of Erwinia Carotovora L-Asparaginase and
[cited by applicant]
Study No. SSARL-DPH-71-02; Toxicity studies on NSC 106977, Erwinia L-asparaginase, MRE, Batch 9 following daily IV administration to a rhesus monkey.
[cited by applicant]
Study No. SSARL-DPH-70-07; Non Diabetogenic action of Erwinia L-Asparaginase when administered intravenously to a rhesus monkey and a rabbit.
[cited by applicant]
WO, International Search Report and Written Opinion for International Patent Application No. PCT/US2022/022635, 16 pages, Jul. 5, 2022.
[cited by applicant]
Erwinaze, “Highlights of Prescribing Information: Erwinaze”, pp. 1-9 (Mar. 2016).
[cited by applicant]